TGNA:FRA
Transgene SA
0,67 €
arrow_downward
−0,15%(−0,00100) 1 p
13. okt, 08:03:08 GMT +2 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse TGNA põhistatistika genereerimine…
Ava
0,67 €
Kõrge
0,67 €
Madal
0,67 €
Turu kapit.
191,94 mln
Keskm. maht
0,00
Maht
0,00
52 näd kõrgeim
1,48 €
52 näd madalaim
0,60 €
Aktsiatulu
−0,17 €
Töötajate arv
152
Ava
0,67 €
Kõrge
0,67 €
Madal
0,67 €
Turu kapit.
191,94 mln
Keskm. maht
0,00
Maht
0,00
52 näd kõrgeim
1,48 €
52 näd madalaim
0,60 €
Aktsiatulu
−0,17 €
Töötajate arv
152
Uudised
Veebiallikatest ja uudistepartneritelt
ChartMill
·
35 minuti eest
Explore the top gainers and losers within the dow jones index in today's session.
Timothy Sykes
·
43 minuti eest
SCNI Regains Nasdaq Compliance As Traders Reassess Risk
Seeking Alpha
·
1 tunni eest
Mentions of inflation have ballooned for tech companies – SoFi (SP500:)
Profiil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Teave üksuse Transgene SA kohta